HRP20060039A2 - Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators - Google Patents

Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Info

Publication number
HRP20060039A2
HRP20060039A2 HR20060039A HRP20060039A HRP20060039A2 HR P20060039 A2 HRP20060039 A2 HR P20060039A2 HR 20060039 A HR20060039 A HR 20060039A HR P20060039 A HRP20060039 A HR P20060039A HR P20060039 A2 HRP20060039 A2 HR P20060039A2
Authority
HR
Croatia
Prior art keywords
benzthiazole
benzimidazole
benzoxazole derivatives
lta4h
group
Prior art date
Application number
HR20060039A
Other languages
English (en)
Croatian (hr)
Inventor
Frank
Scott
Christopher
James
Anne
Cheryl
Brad
Kevin
Wei Jianmei
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20060039A2 publication Critical patent/HRP20060039A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Materials Engineering (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HR20060039A 2003-07-28 2006-01-27 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators HRP20060039A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49071003P 2003-07-28 2003-07-28
PCT/US2004/024050 WO2005012296A1 (en) 2003-07-28 2004-07-27 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Publications (1)

Publication Number Publication Date
HRP20060039A2 true HRP20060039A2 (en) 2006-08-31

Family

ID=34115427

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20060041AA HRP20060041B1 (hr) 2003-07-28 2006-01-27 Derivati benzoimidazola, benzotiazola i benzooksazola i njihova uporaba kao modulatora lta4h
HR20060039A HRP20060039A2 (en) 2003-07-28 2006-01-27 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20060041AA HRP20060041B1 (hr) 2003-07-28 2006-01-27 Derivati benzoimidazola, benzotiazola i benzooksazola i njihova uporaba kao modulatora lta4h

Country Status (29)

Country Link
US (2) US20050043379A1 (xx)
EP (2) EP1660491B1 (xx)
JP (2) JP4726238B2 (xx)
KR (2) KR101149379B1 (xx)
CN (2) CN1856490A (xx)
AR (2) AR045730A1 (xx)
AT (2) ATE405562T1 (xx)
AU (2) AU2004261610B2 (xx)
BR (2) BRPI0413072A (xx)
CA (2) CA2534228A1 (xx)
CY (1) CY1108560T1 (xx)
DE (2) DE602004016002D1 (xx)
DK (2) DK1660492T3 (xx)
ES (2) ES2311858T3 (xx)
HK (2) HK1092790A1 (xx)
HR (2) HRP20060041B1 (xx)
IL (1) IL173372A (xx)
MY (1) MY145080A (xx)
NO (2) NO20060771L (xx)
NZ (2) NZ544970A (xx)
PL (2) PL1660492T3 (xx)
PT (2) PT1660491E (xx)
RU (2) RU2373204C2 (xx)
SG (2) SG129449A1 (xx)
SI (2) SI1660492T1 (xx)
TW (2) TWI362383B (xx)
UA (2) UA82888C2 (xx)
WO (2) WO2005012296A1 (xx)
ZA (2) ZA200601720B (xx)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101149379B1 (ko) * 2003-07-28 2012-06-28 얀센 파마슈티카 엔.브이. 벤즈이미다졸, 벤즈티아졸 및 벤즈옥사졸 유도체 및ｌｔａ4 ｈ 조정자로서의 그의 용도
CN101189012A (zh) * 2005-03-31 2008-05-28 詹森药业有限公司 苯基和吡啶基lta4h调节剂
ME01541B (me) 2005-04-13 2014-04-20 Astex Therapeutics Ltd DERIVATI HIDROKSIBENZAMIDA l NJIHOVA PRIMJENA KAO INHIBITORA HSP90
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
ATE497959T1 (de) * 2005-09-02 2011-02-15 Hoffmann La Roche Benzoxazol-, oxazolopyridin-, benzothiazol- und thiazolopyridinderivate
NZ566788A (en) * 2005-09-21 2012-10-26 Decode Genetics Ehf Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
US7576102B2 (en) 2005-12-21 2009-08-18 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of LTA4H for treating inflammation
EP1968961A2 (en) * 2005-12-21 2008-09-17 Decode Genetics EHF Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
AU2006327243A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation
ES2614090T3 (es) * 2005-12-29 2017-05-29 Celtaxsys, Inc. Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa
US8354434B2 (en) * 2006-01-30 2013-01-15 Purdue Pharma L.P. Cyclourea compounds as calcium channel blockers
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
WO2007144006A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US7989480B2 (en) * 2006-08-04 2011-08-02 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors for treating inflammation
US8115005B2 (en) 2006-08-04 2012-02-14 Decode Genetics Ehf. Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation
WO2008019284A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of lta4h for treating inflammation
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
DE602008002733D1 (de) * 2007-03-08 2010-11-04 Irm Llc Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
JPWO2008120710A1 (ja) * 2007-03-30 2010-07-15 パナソニック電工株式会社 活動強度計
PA8802501A1 (es) * 2007-10-31 2009-06-23 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno, hidrolasa
NZ585085A (en) * 2007-11-16 2012-08-31 Abbott Lab Method of treating arthritis using arylsulfonamide compounds
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2009126806A2 (en) * 2008-04-11 2009-10-15 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
EP2430019B1 (en) * 2009-05-14 2013-09-18 Janssen Pharmaceutica, N.V. Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
CN102442961A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-甲基四氮唑的生产方法
CN102442962A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-烷基四氮唑的生产方法
BR112014009910B1 (pt) 2011-10-25 2020-06-30 Janssen Pharmaceutica N.V. sal di-hidrato de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico, composição farmacêuticae pomada tópica
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
RU2678196C2 (ru) 2013-03-14 2019-01-24 Селтакссис, Инк. Производные 2-фениламино-3-цианопиразоло[1,5-а]пиримидина, полезные в качестве ингибитора лейкотриен-a4-гидролазы
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
BR112015022227A2 (pt) * 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
JP6212644B2 (ja) * 2013-12-17 2017-10-11 イーライ リリー アンド カンパニー フェノキシエチル環状アミン誘導体およびｅｐ４受容体モジュレーターとしてのその活性
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
LT3307734T (lt) 2015-06-09 2020-05-11 Abbvie Inc. Branduolinio receptoriaus moduliatoriai (ror), skirti uždegiminių ir autoimuninių ligų gydymui
EP3559249A1 (en) 2016-12-21 2019-10-30 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of antibodies
CN107663192B (zh) * 2017-11-03 2019-05-10 梯尔希（南京）药物研发有限公司 一种雷贝拉唑杂质的制备方法
EP3801559A4 (en) 2018-05-31 2022-03-02 Celltaxis, LLC METHOD FOR REDUCING LUNG EXACERBATIONS IN PATIENTS SUFFERING FROM RESPIRATORY DISEASE
EP3908278A4 (en) * 2019-01-11 2022-09-28 Naegis Pharmaceuticals Inc. LEUCOTRIENE SYNTHESIS INHIBITORS
CN110026557B (zh) * 2019-05-28 2021-08-27 南方科技大学 一种混合固体颗粒重熔的直写装置及成型方法
CR20230258A (es) * 2020-11-19 2023-09-12 Telo Therapeutics Inc Compuestos y composiciones de moléculas pequeñas
CN113683491A (zh) * 2021-09-01 2021-11-23 王传良 一种4-(2-溴乙基)苯酚的制备方法
CN113735798B (zh) * 2021-09-27 2022-07-12 安徽美致诚药业有限公司 一种盐酸罗沙替丁醋酸酯的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
IT1240598B (it) * 1990-03-13 1993-12-17 Mini Ricerca Scient Tecnolog Derivati amminici ad azione antifungina
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
ID26123A (id) * 1998-02-25 2000-11-23 Genetics Inst Penghambat-penghambat phospholipase a2
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040110757A1 (en) * 2002-03-21 2004-06-10 Thomas Arrhenius Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
KR101149379B1 (ko) * 2003-07-28 2012-06-28 얀센 파마슈티카 엔.브이. 벤즈이미다졸, 벤즈티아졸 및 벤즈옥사졸 유도체 및ｌｔａ4 ｈ 조정자로서의 그의 용도
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof

Also Published As

Publication number Publication date
ATE405562T1 (de) 2008-09-15
AR045729A1 (es) 2005-11-09
NZ544938A (en) 2009-05-31
MY145080A (en) 2011-12-15
US20050043378A1 (en) 2005-02-24
DK1660491T3 (da) 2008-11-10
JP2007500703A (ja) 2007-01-18
KR20060057593A (ko) 2006-05-26
WO2005012297A9 (en) 2007-01-04
HRP20060041B1 (hr) 2014-06-06
KR20060054408A (ko) 2006-05-22
CN100591679C (zh) 2010-02-24
TWI362383B (en) 2012-04-21
US20050043379A1 (en) 2005-02-24
NZ544970A (en) 2009-02-28
CN1860117A (zh) 2006-11-08
BRPI0413072A (pt) 2006-10-03
RU2359970C2 (ru) 2009-06-27
JP4726238B2 (ja) 2011-07-20
TW200523255A (en) 2005-07-16
ZA200601720B (en) 2007-11-28
ATE403654T1 (de) 2008-08-15
WO2005012297A1 (en) 2005-02-10
PT1660491E (pt) 2008-10-10
CA2534228A1 (en) 2005-02-10
PT1660492E (pt) 2008-11-13
NO20060771L (no) 2006-04-21
HK1090359A1 (en) 2006-12-22
SG129449A1 (en) 2007-02-26
RU2373204C2 (ru) 2009-11-20
WO2005012296A1 (en) 2005-02-10
EP1660492A1 (en) 2006-05-31
CA2534212A1 (en) 2005-02-10
JP2007500706A (ja) 2007-01-18
SG130192A1 (en) 2007-03-20
DE602004015620D1 (de) 2008-09-18
ES2313079T3 (es) 2009-03-01
KR101149379B1 (ko) 2012-06-28
TW200520756A (en) 2005-07-01
EP1660491B1 (en) 2008-08-06
ZA200601716B (en) 2007-05-30
BRPI0412345A (pt) 2006-10-03
HK1092790A1 (en) 2007-02-16
PL1660491T3 (pl) 2009-01-30
UA87986C2 (xx) 2009-09-10
AU2004261628B2 (en) 2011-05-12
SI1660491T1 (sl) 2009-02-28
AR045730A1 (es) 2005-11-09
HRP20060041A2 (en) 2006-11-30
IL173372A0 (en) 2006-06-11
RU2006102508A (ru) 2006-07-27
CN1856490A (zh) 2006-11-01
AU2004261628A1 (en) 2005-02-10
ES2311858T3 (es) 2009-02-16
EP1660491A1 (en) 2006-05-31
NO20060823L (no) 2006-03-15
CY1108560T1 (el) 2014-04-09
DE602004016002D1 (de) 2008-10-02
IL173372A (en) 2010-11-30
AU2004261610A1 (en) 2005-02-10
SI1660492T1 (sl) 2009-02-28
UA82888C2 (en) 2008-05-26
DK1660492T3 (da) 2008-11-03
EP1660492B1 (en) 2008-08-20
RU2006102510A (ru) 2006-07-27
PL1660492T3 (pl) 2009-01-30
AU2004261610B2 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
HRP20060039A2 (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
BRPI0607742A2 (pt) moduladores de fenil e piridil lta4h
RS53348B (en) PROCEDURE FOR THE PREPARATION OF 3-SUBSTITUTED 2-AMINO-5-HALOBENZAMIDES
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
BRPI0508464A (pt) sulfonilpirróis
TW200510353A (en) Alpha substituted carboxylic acids as PPAR modulators
DK1981874T3 (da) Aminophenylderivater som nye inhibitorer af histondeacetylase
NO20053810D0 (no) Thiofenkarboksamider som inhibitorer av enzymet IKK-2
RS52392B (en) SUBSTITUTED PYRIDINONES AS P38 MAP KINASE MODULATORS
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE203747T1 (de) 5-azabicyclo(3.1.0.)hexylalkyl-2-piperidone und - glutarimide als neurokinin receptor antagonisten.
ATE547395T1 (de) Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors
UA85593C2 (xx) Похідні хіназолінону як інгібітори parp$производные хиназолинона как ингибиторы parp
AR052673A1 (es) Derivados del 1,5-diarilpirrol,su preparacion y su aplicacion en la terapeutica
RS53180B (en) NEW SEH INHIBITORS AND THEIR USE
YU45401A (sh) Antikancerogena kombinacija
ATE466853T1 (de) Cgrp-rezeptorantagonisten
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
RS52427B (en) ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICALALLY ACCEPTABLE SALTS AND MIXTURES, AND THEIR USE
EA200600607A1 (ru) Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы
ATE513818T1 (de) Chinazolinonderivate als tubulinpolymerisationshemmer
PT1377574E (pt) 6-fenilbenzonaftiridinas
EA200600601A1 (ru) Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20090722

Year of fee payment: 6

OBST Application withdrawn